News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
31,275 Results
Type
Article (4002)
Company Profile (2)
Press Release (27270)
Multimedia
Podcasts (32)
Webinars (2)
Section
Business (10967)
Career Advice (85)
Deals (1361)
Drug Delivery (24)
Drug Development (5200)
Employer Resources (10)
FDA (926)
Job Trends (821)
News (16831)
Policy (1373)
Tag
2027 Biotech Bay Standard (1)
40 Under 40 (1)
Academia (104)
Accelerated approval (9)
ADA (8)
Adcomms (1)
Allergies (9)
Alliances (2727)
ALS (3)
Alzheimer's disease (147)
Antibody-drug conjugate (ADC) (58)
Approvals (957)
Artificial intelligence (63)
ASCO (24)
Autoimmune disease (29)
Automation (5)
Bankruptcy (6)
Belgium (1)
Best Places to Work (574)
BIO (1)
Biologics (3)
BIOSECURE Act (1)
Biosimilars (36)
BioSpace Insights (6)
Biotechnology (2)
Bispecific (5)
Bladder cancer (11)
Brain cancer (6)
Breast cancer (91)
Cancer (533)
Cardiovascular disease (32)
Career advice (80)
Career pathing (2)
CAR-T (10)
CDC (3)
CDMO (14)
Cell therapy (52)
Cervical cancer (7)
Clinical research (4371)
Collaboration (223)
Commercialization (1)
Company closure (1)
Compensation (6)
Complete response letters (10)
COVID-19 (230)
C-suite (141)
Cystic fibrosis (9)
Data (396)
Depression (6)
Dermatology (4)
Diabetes (45)
Diagnostics (333)
Digital health (3)
Diversity, equity & inclusion (1)
Drug discovery (22)
Drug pricing (30)
Drug shortages (4)
Duchenne muscular dystrophy (28)
Earnings (2626)
Editorial (8)
Employer branding (5)
Employer resources (8)
ESMO (20)
Events (2928)
Executive appointments (101)
Eye disease (5)
FDA (1119)
Frontotemporal dementia (1)
Funding (119)
Gene editing (3)
Generative AI (6)
Gene therapy (49)
GLP-1 (148)
Government (260)
Guidances (11)
Healthcare (633)
Hematology (12)
HIV (6)
Huntington's disease (17)
Idiopathic pulmonary fibrosis (3)
IgA nephropathy (9)
Immunology and inflammation (49)
Immuno-oncology (10)
Indications (14)
Infectious disease (250)
Inflammatory bowel disease (20)
Inflation Reduction Act (2)
Influenza (11)
Intellectual property (5)
Interviews (10)
IPO (453)
IRA (11)
Job creations (261)
Job search strategy (70)
JPM (11)
Kidney disease (15)
Labor market (8)
Layoffs (67)
Leadership (5)
Legal (291)
Licensing (11)
Liver cancer (15)
Longevity (4)
Lung cancer (112)
Lung diease (3)
Lymphoma (62)
Machine learning (4)
Management (2)
Manufacturing (88)
MASH (29)
Medical device (195)
Medtech (200)
Mergers & acquisitions (928)
Metabolic disorders (203)
mRNA (25)
Multiple sclerosis (45)
NASH (6)
Neurodegenerative disease (51)
Neuropsychiatric disorders (14)
Neuroscience (287)
Neurotech (1)
NextGen: Class of 2026 (241)
Non-profit (182)
Now hiring (8)
Obesity (144)
Opinion (32)
Ovarian cancer (8)
Pain (3)
Pancreatic cancer (13)
Parkinson's disease (25)
Partnered (1)
Patents (18)
Patient recruitment (17)
Patient selection (4)
Peanut (3)
People (4404)
Pharmacy benefit managers (4)
Phase 1 (1235)
Phase 2 (1734)
Phase 3 (1828)
Pipeline (563)
Policy (36)
Postmarket research (303)
Preclinical (387)
Press Release (1)
Prostate cancer (8)
Psychedelics (6)
Radioligand (1)
Radiopharmaceuticals (15)
Rare diseases (74)
Real estate (221)
Recruiting (5)
Regulatory (1189)
Reports (7)
Research institute (121)
Resumes & cover letters (12)
Rett syndrome (2)
RNA editing (2)
RSV (5)
Schizophrenia (16)
Series A (27)
Series B (21)
Sickle cell disease (3)
Special edition (7)
Spinal muscular atrophy (61)
Sponsored (1)
Startups (222)
Stomach cancer (6)
Substance use disorders (1)
Supply chain (9)
Switzerland (1)
Tariffs (26)
The Weekly (32)
Vaccines (62)
Venture capital (19)
Weight loss (98)
Wet AMD (1)
Women's health (4)
Date
Today (5)
Last 7 days (24)
Last 30 days (123)
Last 365 days (1224)
2026 (1046)
2025 (1158)
2024 (1508)
2023 (1519)
2022 (3097)
2021 (2756)
2020 (2408)
2019 (1758)
2018 (1433)
2017 (1462)
2016 (1340)
2015 (1645)
2014 (1194)
2013 (1031)
2012 (1165)
2011 (1251)
2010 (1175)
Location
Africa (69)
Alabama (3)
Arizona (17)
Asia (1503)
Australia (230)
California (579)
Canada (86)
China (107)
Colorado (5)
Connecticut (46)
Delaware (3)
Europe (6949)
Florida (24)
Georgia (15)
Illinois (51)
India (6)
Indiana (39)
Japan (25)
Kansas (1)
Kentucky (2)
Louisiana (1)
Maryland (18)
Massachusetts (375)
Michigan (15)
Minnesota (40)
Missouri (10)
Nevada (3)
New Hampshire (1)
New Jersey (81)
New York (178)
North Carolina (41)
Northern California (369)
Ohio (3)
Oklahoma (1)
Oregon (3)
Pennsylvania (41)
Rhode Island (2)
South America (63)
Southern California (155)
Tennessee (2)
Texas (39)
United States (1667)
Utah (15)
Vermont (1)
Virginia (7)
Washington D.C. (4)
Washington State (92)
Wisconsin (3)
31,275 Results for "roche boehringer mannheim".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have proposed a clause to the country’s healthcare reforms set to take effect Jan. 1.
October 23, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.
October 22, 2026
·
2 min read
·
Tristan Manalac
Eye disease
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
September 24, 2026
·
2 min read
·
Annalee Armstrong
Diabetes
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
The mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from the $2.7 billion acquisition of Carmot Therapeutics as well as partner Zealand Pharma.
September 22, 2026
·
2 min read
·
Annalee Armstrong
Obesity
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary Chugai Pharmaceutical.
September 29, 2026
·
2 min read
·
Tristan Manalac
Deals
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases.
September 24, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies
· New research team expands capabilities at Boehringer’s U.S. R&D site in Ridgefield, Connecticut.
July 9, 2026
·
1 min read
Pipeline
Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’
Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year.
August 24, 2026
·
1 min read
·
Tristan Manalac
Obesity
Roche expands obesity R&D footprint with Rona deal worth $1B+
Roche has gained access to a genetic obesity approach from China’s Rona Therapeutics for up to $100 million in upfront and near-term payments.
October 13, 2026
·
2 min read
·
Michael Gibney
Deals
Roche returns to Hansoh with broad $15B ADC deal
Roche is offering $400 million upfront and over $15 billion in biobucks to team up with Hansoh Pharmaceutical in hopes of developing a portfolio of new antibody-drug conjugates using the latter’s in-house tech.
October 19, 2026
·
1 min read
·
Gabrielle Masson
1 of 3,128
Next
